Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Laboratory of Hematologic Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
J Pediatr. 2021 Feb;229:267-274.e3. doi: 10.1016/j.jpeds.2020.08.063. Epub 2020 Sep 18.
To analyze the clinical characteristics and prognosis of pediatric hemophagocytic lymphohistiocytosis (HLH) associated with histiocytic necrotizing lymphadenitis (HNL).
We retrospectively collected the clinical data of all children with HNL-HLH enrolled in Beijing Children's Hospital from 2007 to 2019. The control patients with Epstein-Barr virus-associated HLH and simple HNL (not associated with HLH) were case matched (1:2). The clinical features and prognosis were analyzed by case-control study. Cases of HNL-HLH in the literature were reviewed.
The male-to-female ratio of the 13 patients in our center was 9:4. The mean age of the patients at disease onset was 8.1 ± 1.2 years, younger than that of the 16 patients in the literature (P = .017). Clinical presentations, especially rash and splenomegaly, and laboratory examination of HNL-HLH group were statistically different from Epstein-Barr virus-HLH group, simple HNL group, and patients reported in the literature (P < .05). Three patients were treated with immunosuppressive drugs or chemotherapy owing to poor control of HLH. One patient died, and all 12 remaining patients survived, 2 of which developed autoimmune diseases. Kaplan-Meier survival curves showed no statistical difference among the 3 groups (P > .05).
HNL-HLH is more common in school- and preschool-age children. Most patients have a favorable prognosis. Some patients suffer from relapses or develop autoimmune diseases. Prolonged follow-up should be carried out for patients with HNL-HLH.
分析与组织细胞坏死性淋巴结炎(HNL)相关的儿童噬血细胞性淋巴组织细胞增生症(HLH)的临床特征和预后。
我们回顾性收集了 2007 年至 2019 年期间北京儿童医院所有 HNL-HLH 患儿的临床资料。采用病例对照研究,将 Epstein-Barr 病毒相关性 HLH 患儿和单纯 HNL(与 HLH 无关)患儿按 1:2 比例进行病例匹配。分析临床特征和预后。对文献中 HNL-HLH 病例进行复习。
本中心 13 例患儿中男女性别比为 9:4。起病时患儿的平均年龄为 8.1±1.2 岁,小于文献中 16 例患儿的年龄(P=0.017)。HNL-HLH 组的临床表现,特别是皮疹和脾肿大,以及实验室检查与 Epstein-Barr 病毒-HLH 组、单纯 HNL 组和文献报道的患者均有统计学差异(P<0.05)。由于 HLH 控制不佳,3 例患儿接受免疫抑制剂或化疗治疗。1 例患儿死亡,其余 12 例患儿存活,其中 2 例发展为自身免疫性疾病。Kaplan-Meier 生存曲线显示 3 组间无统计学差异(P>0.05)。
HNL-HLH 多见于学龄前期和学龄期儿童。大多数患者预后良好。部分患者出现复发或发生自身免疫性疾病。应对 HNL-HLH 患儿进行长期随访。